Immunotherapy combo shows promise for Hard-to-Treat stomach cancers

NCT ID NCT03257163

First seen Jan 25, 2026 · Last updated May 08, 2026 · Updated 12 times

Summary

This study is for people with specific types of stomach cancer (mismatch repair deficient or Epstein-Barr virus positive) that can be surgically removed. It tests whether giving the immunotherapy drug pembrolizumab before and after standard chemotherapy and radiation can help prevent the cancer from coming back. About 40 participants will receive this combination treatment and be followed for three years to see how well it works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Emory University

    Atlanta, Georgia, 30308, United States

  • Montefiore Medical Center

    The Bronx, New York, 10467, United States

  • RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton

    Hamilton, New Jersey, 08690, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903, United States

Conditions

Explore the condition pages connected to this study.